For the second year, Fresenius Medical Care North America (FMCNA), the largest provider of dialysis products and services, will serve as National Presenting Sponsor for the National Kidney Foundation’s 2019 Kidney Walks. As part of that commitment, the company will rally employees for a National Team in an attempt to exceed their record participation in 2018, which brought thousands of employees and their families out to support people affected by kidney disease.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced today that it has appointed Dr. Frank Maddux as Global Chief Medical Officer and Dr. Robert Kossmann as Chief Medical Officer for North America. In addition, Dr. Jeffrey Hymes, Chief Medical Officer for Fresenius Kidney Care, will expand his role to also serve as Senior Vice President of Clinical and Scientific Affairs for Fresenius Medical Care North America.
FDA Grants Breakthrough Device Designation to FMCNA’s Software for Fluid Management During Hemodialysis
Fresenius Medical Care North America’s Renal Therapies Group, the leading provider of kidney care products, announced today that the U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to its computer-assisted ultrafiltration (UF) control software currently in development to improve fluid management during hemodialysis and personalize treatments.
Fresenius Medical Care North America (FMCNA), the nation’s leading provider of kidney care products and services, has announced a 2019 commitment of $195,000 to support nonprofit patient education programs that help people with chronic kidney disease (CKD) make informed treatment choices including transplant and home dialysis.
Fresenius Medical Care has successfully completed the acquisition of NxStage Medical, Inc., which develops, produces and markets an innovative product portfolio of medical devices for use in home dialysis and critical care. The acquisition will enable Fresenius Medical Care to leverage its manufacturing, supply chain and marketing competencies across the dialysis products, services and Care Coordination businesses in a less labor- and capital-intensive care setting.
Fresenius Medical Care North America’s Renal Therapies Group today announced market availability of the 2008T BlueStar™ hemodialysis machine. With evolved technologies and elevated performance across more than 30 unique enhancements, the 2008T BlueStar machine represents the most comprehensive upgrade in company history.
Fresenius Kidney Care maintained its 5-Diamond status at 99.96 percent of its in-center and home hemodialysis programs, while 100 percent of enrolled Fresenius Kidney Care acute care dialysis centers achieved 5-Diamond status.
Fresenius Medical Care North America’s Renal Therapies Group announces the publication of a study in the Journal of Renal Nutrition examining the real-world effectiveness of sucroferric oxyhyroxide (Velphoro®) in managing serum phosphorous levels in hemodialysis patients with chronic kidney disease
1 in 6 Outpatient Dialysis Patients with AKI Lasting More Than 90 Days Still Recover Kidney Function
Fresenius Medical Care North America (FMCNA), the nation’s leading renal care company, announces preliminary results from an analysis of new data on more than 9,000 patients with acute kidney injury (AKI) treated at Fresenius Kidney Care outpatient dialysis centers.
Fresenius Medical Care North America (FMCNA), the world’s largest provider of dialysis products and services, raised more than $800,000 for the National Kidney Foundation (NKF) centerpiece Kidney Walk fundraiser, the nation’s largest fundraising initiative to fight kidney disease. The company, which served as National Presenting Sponsor, bested its own record set last year by more than $100,000, raising the most ever by a National Team.
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today released the following statement in response to the defeat of the ballot initiative Proposition 8 in California.
Lower Hospitalization Rates Observed Among Patients New to Hemodialysis with RBV-M Utilizing Crit-Line®
Fresenius Medical Care’s Renal Therapies Group today announced the results of four studies utilizing the Crit-Line® monitor that examine how relative blood volume monitoring (RBV-M) can help improve patient outcomes. All four abstracts were accepted for poster presentation at the 2018 American Society of Nephrology’s (ASN) Kidney Week Symposium in San Diego, Calif.